Determination Concentrations of Tissue Factor Pathway Inhibitor and their Changes during Estrogen Replacement Therapy

Czech version

Authors: Tomáš Fait ¹; B. Trnková ³; M. Koštířová ³; M. Vráblík ²
Authors‘ workplace: Gynekologicko-porodnická klinika VFN Praha a 1. LF UK, Praha, přednosta prof. MUDr. A. Martan, DrSc. ¹; III. interní klinika VFN Praha a 1. LF UK, Praha, přednosta prof. MUDr. Š. Svačina, DrSc. ²; Ústav klinické biochemie VFN Praha a l. LF UK, Praha, přednosta prof. MUDr. T. Zima, DrSc. ³
Published in: Ceska Gynekol 2007; 72(5): 343-347
Category: Original Article

Overview

Objective:
The purpose of the present study was to determine changes of tissue factor pathway inhibitor (TFPI) as a biochemical risk factors of thromboembolism during the use of different administration methods of the early estrogen replacement therapy.

Design:
Prospective randomized cross-over trial.

Setting:
General Faculty Hospital Prague.

Methods:
In a 12-week prospective, randomized, interventional, cross-over trial, estradiol was administered orally in a dose of 2 mg daily or transdermally in a dose of 0,05 mg daily. Forty-five healthy postmenopausal women were included into the study within 12 weeks after the hysterectomy and ovariectomy (surgical castration). Forty-one women completed the study and their data were analyzed. The average age was of 49 ± 6 years. An enzymatic method (IMUBIND Total TFPI ELISA test) was employed for the determination of TFPI.

Results.
After the oral therapy, the average value of TFPI decreased statistically significantly (p

Key words:
estrogen replacement therapy, thromboembolism, TFPI